# Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration

> **NCT07052578** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 400 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07052578
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-30
- **Primary completion:** 2028-06-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07052578

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07052578, "Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07052578. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*